Sirona Biochem Billion Dollar Skin Lightening Opportunity With TFC-1067 Compound
Sirona Biochem is the center of attention on signing a landmark licensing deal for its proprietary skin-lightening compound with a company topping billions of dollars in sales. The signing of the deal comes at a time of growing demand for skin lightening products with the market poised to reach $20 billion by 2022.
Sirona | Rodan + Field Deal
The cosmetic ingredient and drug discovery company remain well positioned to generate significant value on the burgeoning skin lightening market. Backed by a proprietary platform technology that has already given rise to TFC-1067, the company is already eliciting strong interest from some of the biggest skin care brands.
The signing of a term sheet with Rodan + Fields LLC for proprietary TFC-1067 compound might as well have opened the door for the company to generate significant value going forward. Under the terms of the agreement, Sirona Biochem is to manufacture and supply TFC-1067 for use by Rodan + Fields in its products.
The company stands to generate significant revenues on the sale of the skin-lightening compound. In addition, it is entitled to a fee by Rodan + Fields on the signing of the definitive agreement. The company will also earn milestone fees on each product that Rodan + Fields sales, utilizing the skin-lightening agent TFC-1067. The two have also agreed to establish regular formal meetings to explore future opportunities.
A partnership with Rodan + Fields marks an important milestone as Sirona Biochem seeks to generate significant value from its proprietary skin lighting compound. Skincare brand Rodan + Fields has generated more than $1 billion in sales since 2016, seen as an ideal partner for Sirona after years of TFC-1067 R&D investments.
The compound stands out in part because it is superior to current actives in the market in addition to being safe and free of hydroquinone. TFC-1067 has also proved to be superior in the treatment of dyschromia with no adverse effects.
The use of TFC-1067 in Rodan + Fields products opens the door for Sirona Biochem to recoup a substantial amount of money spent on the development of the skin lighting agent.
“After many years of developing TFC-1067 with the support of the French government and European Union in the Cosmetic Valley, France, we are excited to partner with skincare industry leader Rodan + Fields. This marks an important milestone for Sirona Biochem,” explained Dr. Howard Verrico CEO of Sirona Biochem.
Skin Lightening Opportunity
Sirona Biochem is on the cusp of something great in the skin care market. The company has already secured a U.S patent for the flagship skin-lightening agent TFC-1067 further strengthening its IP portfolio. The new patent adds to similar patents granted in Germany, France, and the United Kingdom.
With the patent, the company can now pursue licensing deals similar to the one signed with Rodan + Fields. Such deals should go a long way in helping the company strengthen its revenue streams through licensing fees as well as milestone fees and royalty payments.
Sirona Biochem is currently in advanced negotiations in North America and Asia as it eyes licensing deals for the skin-lightening compound. Given the potential impact of TFC-1067 in the multi-billion dollar skin lightening market, the company could be a potential acquisition target for big companies wishing to own TFC-1067 outright.
- Published in Bio technology, Dermatology, Sirona Biochem, Skin Care
Sirona Biochem to Exhibit at the Shanghai China Beauty Expo 2018
Momentum Public Relations
Press Release: April 30 2018
Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that they will be exhibitors at China Beauty Expo (CBE) 2018. The trade show will be held May 22-24 in Shanghai, a growing hub in the cosmetic space.
The China Beauty Expo is the lead international beauty trade fair, providing a platform for key professionals in the cosmetic industry to meet and collaborate to enter the Asian market. Asia is currently the biggest market for beauty personal care ingredients and China specifically is the second biggest cosmetic market, with continued double-digit growth. The company looks forward to meeting with professionals from over 30 countries and discussing partnering opportunities.
As a member of the Cosmetic Valley, the company will also benefit from press and advertisement campaigns before, during and after the show. All exhibitors from the Cosmetic Valley will be part of the media promotional campaign for China Beauty Expo, along with featured pages in all show material including the May edition of Cosmetic News, which is sent out to 100,000 industry professionals in China. Sirona Biochem would like to extend their gratitude to the Normandy District and the Normandy Development Agency for sponsoring the trip.
While Sirona continues in its negotiations with a lead global partner alongside advanced due diligence from other partners, Sirona Biochem aims to expand its corporate presence in the Asian market. The company believes that its platform technology and pipeline will be of great interest to the CBE attendees, especially within the expanding Asian market.
“Ultimately, management’s responsibility is to bring as many players to the table to create a competitive environment on a licensing deal for 1067 and will continue such efforts until a definitive agreement is concluded,” said CEO, Dr. Howard Verrico.
With the extensive family of skin-lighteners within Sirona’s portfolio and novel LIP-01 anti-wrinkle compound, Sirona Biochem is well-positioned to meet the needs of the Asian consumers.
About China Beauty Expo
In its 23rd year, this show attracts a variety of beauty professionals, including importers, distributors, retailers and even beauty salons. Exhibitors are categorized by cosmetech, cosmetics and professional beauty.
In 2017, there were over 400,000 attendees from around the globe, including China, Korea, and the USA. This year, an anticipated 500,000 visitors will attend, alongside the 3,500 exhibitor booths. More specifically, there will be 1000 international brands from over 34 countries. Sirona Biochem will be one of the exhibitors within the Cosmetic Valley section.
For more information, visit: https://www.chinabeautyexpo.com/en/homepage.html
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
Sirona Biochem Announces Chief Scientific Officer to Present at Adaptations in Polar Environments and Biomimicry
Momentum Public Relations
Press Release: February 2, 2018
Sirona Biochem Corp. (TSX VENTURE: SBM)(FRANKFURT: ZSB)(XETRA: ZSB) (the “Company”) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Paris symposium: Adaptations in Polar Environments and Biomimicry.
The conference showcases animal adaptations to extreme polar environments, and how these adaptations have inspired commercial technology. Dr. Deliencourt-Godefroy will present on February 3rd at 11:00 AM CET, on the glycoproteins that were discovered in Arctic fishes and her advancement of the technology in human cell preservation. Her talk can be streamed live at:
https://cite-sciences.ubicast.tv/permalink/l1253c0f84c1fnr2u6ni/iframe/
NB: the conference is held in French.
About Milieux Polaires et Biomimétisme and Poles Actions
The yearly symposium is organized by Poles Actions and is dedicated to polar biomimicry.
The association of Poles Actions is intended to promote the knowledge and the protection of Arctic and Antarctic ecosystems through awareness, education and support for research in polar and subpolar regions. It acts as a nonpartisan, objective and scientifically credible channel of communication, based on the activities and experience of its members and external stakeholders. It organizes educational interventions, exhibitions, conferences and scientific expeditions to help publicize and protect these fragile ecosystems. For more information, visit: http://www.ourspolaire.org/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Sirona Biochem
Sirona Biochem Announces Development of Anti-Wrinkle Treatment and Update from J.P. Morgan Healthcare Conference
Momentum Public Relations
Press Release: January 31, 2018
Sirona Biochem Corp. (TSX VENTURE: SBM)(FRANKFURT: ZSB)(XETRA: ZSB) (the “Company”) announced today that the Company is developing an anti-wrinkle therapy.
The compound, LIP-01, was discovered to have a novel mechanism of action and will enter pre-clinical studies as a plumping/smoothing ingredient for aging skin. LIP-01 was tested on human skin cells called “normal human dermal fibroblasts” (NHDF). The treatment of the cells with the compound LIP-01 resulted in an up-regulation of gene expression leading to an activation of the signaling pathway of lipids. The presence of lipid vesicles in fibroblasts treated by compound LIP-01 showed cell differentiation of fibroblasts into lipo-fibroblasts. The increased synthesis of lipids in these cells leads to a plumping effect which is anticipated to fill wrinkles. Sirona’s scientists have also observed proliferation and preservation of fibroblasts when LIP-01 was added, important in countering the declining number of cells observed in aged skin. The Company and its consultants are building a development plan for this compound which includes a proof-of-concept clinical trial.
Loss of elasticity and degradation of fat tissue are two markers seen in aging skin, leading to the appearance of lines and wrinkles. Compounds that increase the number and volume of adipocytes (fat cells) can act as plumping, volumizing, and densifying skin agents, thereby reducing the visibility of wrinkle and potentially providing a more youthful look. The global anti-aging market is expected to grow to over $330 Billion USD by 2021 (Reuters, June 2017). Novel solutions are actively being sought out by the dermatology industry to address this.
“There was tremendous interest in these initial results when presented to companies on our recent trip to San Francisco during the J.P. Morgan Healthcare Conference,” said Dr. Howard Verrico, CEO. “The effects of compound LIP-01 on the skin cells suggest that this compound can contribute to improving the quality of dry skin and reduce the signs of aging. Our goal is to develop LIP-01 as a non-invasive treatment for wrinkles by a mechanism very different from dermal fillers and Botox®1.”
According to the American Society of Plastic Surgeons, using Botox® treatment for wrinkles is the most common cosmetic operation performed, generating 3 billion USD in revenue annually. However, Botox® is generally limited to use on the upper third of the face, specifically the frown lines between the eyebrows. Botox® also requires administration by a properly trained professional.
“Our scientists believe these two obstacles could be overcome with a topical therapy which could either replace or augment Botox® treatments. If clinically successful, LIP-01 could exceed Botox in market potential,” Verrico said.
In San Francisco, the Sirona team met with existing potential partners and established new ones in the cosmetic and dermatology industry to discuss both the skin-lightening portfolio and introduce LIP-01. The Company is pleased with the positive outcome of each meeting and is looking forward to continuing discussions during the American Academy of Dermatology Summit next month in San Diego. Several leading dermatologists who were excited by the data will be meeting with the Company to discuss next steps. Sirona Biochem is now in discussions with over a dozen companies regarding various aspects of the Company’s pipeline.
Sirona’s management also met with Obagi’s medical strategic development team to explore opportunities to commercialize its next-generation skin lighteners under a new agreement. The new skin lighteners are superior to its first-generation ones, having a simple synthetic pathway which results in a lower cost of goods. The first-generation compound, TFC-849, has proven difficult to manufacture in a commercially viable process. Obagi Medical under its new ownership will not be proceeding with the development of TFC-849. As a result, Sirona’s skin lightener library is no longer encumbered by restrictive clauses under the former licensing agreement and is now available for licensing world-wide.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
(1) BOTOX COSMETIC® is a registered trademark of Allergan Inc.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Sirona Biochem
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Momentum Public Relations
Press Release: August 23, 2017
VANCOUVER, BC–(Marketwired – August 23, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces an extension to the term of 8,850,770 common share purchase warrants (the “Warrants”) originally issued on March 6, 2014. The warrants were issued as part of a private placement. The expiry dates will be extended as follows:
March 6, 2014 | |
Number of Warrants: | 8,850,770 |
Original Expiry Date of Warrants: | March 6, 2017 |
New Expiry Date of Warrants: | November 30, 2017 |
Exercise Price of Warrants: | $0.25 |
All other terms of the Warrants will remain unchanged.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem, Technology
Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library
Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library
Momentum Public Relations
Press Release: July 6, 2017
VANCOUVER, BC–(Marketwired – July 06, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) (the “Company“) announced positive preclinical efficacy data for its library of skin lightening compounds.
The study was conducted at Bioalternatives in France, a contract research organization specializing in cellular and molecular pharmacology. The study looked at each of six compounds’ ability to inhibit melanin synthesis induced by L-tyrosine for 10 days in normal human epidermal melanocytes. Results showed a significant decrease in melanin synthesis with a similar efficacy across the library. Inhibiting melanin production is the principal mechanism of action for the majority of skin lighteners in clinical use.
“In December 2016, we announced the completion of our skin lightening library, with plans to begin testing in 2017,” said Dr. Howard Verrico, CEO. “The positive efficacy of these compounds adds value to a licensing transaction as it increases the opportunity for commercialization in various markets and therapeutic areas. Moreover, this data will be used to support and strengthen our IP in this area.”
Sirona has shared these results with the multinational companies currently working towards a license to commercialize TFC-1067.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Life Sciences, News Home, Sirona Biochem
The Fountain of Youth May Be Just Around the Corner In Vancouver
The Fountain of Youth May Be Just Around the Corner In Vancouver
Sirona Biochem makes safer and more effective cosmeceuticals
Vancouver-based Sirona Biochem is on track to crack the global market for skin lightening products, a market that has been predicted by Global Industry Analysts to hit US$23 billion by 2020. If that isn’t enough the company is also developing a product designed to forestall facial aging. Zion Market Research pegs the global anti-aging market at US$216.52 billion by 2021. The Company’s skin lightening products are far safer and far more effective than those which are currently on the market.
In hindsight it is not that surprising that Vancouver is becoming a hotbed of discovery when it comes to turning back the ravages of time. Botox as we know it today for the cosmetics industry, after all, was popularized in Vancouver by the husband and wife team of ophthalmologist Jean Carruthers and dermatologist Alistair Carruthers. They discovered that a toxin named botox helped eradicate the lines and wrinkles caused by aging.
Sirona Biochem Corp. (TSX-V:SBM) is a discovery and development stage biochem company that has developed a proprietary way to treat carbohydrate molecules using fluorination chemistry. This process prevents molecules from breaking down when exposed to enzymes. This now opens the door to developing a new field of therapeutics.
The company also has an anti-aging product based on synthesizing the glycoprotein found in the blood serum of Antarctic water fish and is currently in the testing and validation stage. The glycoprotein helps preserve the fish and its cells from the freezing water. When applied to humans, it helps prevent skin cells from dying, and also protects them from the harsh glare of ultra-violet radiation.
The good news for Sirona, however, doesn’t stop there. The company believes their stabilized carbohydrate molecules have applications in the treatment of cancer, pain, diabetes and inflammation. Sirona has developed an SGLT2 inhibitor as a Type 2 Diabetes treatment. Research and consulting firm Global Data has predicted that the global type 2 diabetes market will almost double from US$31.2 billion in 2015 to US58.7 billion by 2025.
SGLT2 inhibitors are a recent development in the fight against Type 2 diabetes. Most traditional diabetes treatments work by controlling insulin production or regulating blood sugar levels. SGLT2 inhibitors work by acting in the kidneys to reduce the reabsorption of glucose into the bloodstream.
Sirona’s strategy is to do the basic discovery and development work on a given product, and then to license the technique or joint venture it for commercialization, marketing and distribution. In 2014 the company signed a licensing agreement with Wanbang Biopharmaceuticals for the Chinese market. Wanbang will develop and commercialize Sirona’s SGLT2 inhibitor exclusively in the People’s Republic of China. The company also has a licensing agreement with Obagi Medical Products for a skin lightening agent.
Sirona Biochem was founded in 2009 by CEO Dr. Howard Verrico. The first thing Verrico did was to acquire the exclusive global license from TFChem for its proprietary SGLT2 Inhibitor. TFChem is based in Rouen, France. Verrico thought enough of TFChem’s research that he then went on to acquire TFChem as a wholly-owned subsidiary from its founder Dr. Geraldine Deliencourt-Godefroy. She then became Sirona’s Chief Science Officer and largest shareholder. TFChem now acts as Sirona’s research and development laboratory. A respected scientist, Deliencourt-Godefroy has also received a variety of honours in France including the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.
The company sees the cosmetic and cosmeceutical industry as its first major market penetration target for two important reasons. The first is that, as noted above, the financial reward for creating a fountain of youth will be immense. Secondly, the amount of regulatory testing for cosmetics is miniscule when compared to that involved in the pharmaceutical industry. The company intends to use the cash flow created by its anti-aging platform and skin colour lightening products, to finance the creation of more traditionally flavoured therapies for things like cell preservation and anti-inflammatories.
The company’s development focus is based on three high-return fields of discovery and development:
- Therapeutics: diabetes, anti-inflammatories and anti-infectives
- Cosmeceuticals: anti-aging and depigmenting agents
- Biological Ingredients: inducers and adjuvants for biological development and preservation.
With an SLGT2 inhibitor in the pre-clinical stage and four cosmetic products in the testing and validation phase, the company has received revenues and will continue to do so in the future from Wanbang for its SLGT2 inhibitor. Sirona also receives revenue from Obagi Medical products for a skin lightener, one of three skin lightening agents under development. It is also working on an acne treatment, an anti-inflammatory and an anti-infective.
Much of Sirona’s work is ground-breaking. Stabilizing carbohydrate molecules opens up new fields for therapeutic interventions and may rejuvenate older treatments which became stalled. Synthesizing the glycoprotein found in the blood serum of Antarctic fish may produce a product that slows down the aging of skin. One way to illustrate its potential value is that when TFChem first synthesized the glycoprotein, cosmetic giant L’Oreal Group, the world’s largest cosmetics company slapped a field-of-use patent on it. As it turns out the first synthesis was not stable, but the later ones were, and L’Oreal was out of luck.
While Sirona is concentrating on developing cosmetic products, it hasn’t neglected the medical side of things. The company has a pipeline of products that are heading towards the market. The anti-aging compound is now in the testing and validation phase.
The company has a 52-week high of $0.20 and a 52-week low of $0.12. As of June 16, 2017, it was trading at $0.17. And if you were wondering, Sirona is the name of the Celtic goddess of healing.
- Published in Bio technology, Blog, Sirona Biochem, Technology
Sirona Biochem Closes Convertible Note Financing
Sirona Biochem Closes Convertible Note Financing
Momentum Public Relations
Press Release: June 5, 2017
VANCOUVER, BC–(Marketwired – June 05, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) is pleased to announce that it has closed the non-brokered private placement (the “Private Placement”) of convertible notes (“Notes”). The financing was oversubscribed, resulting in gross proceeds of $587,000. Each Note is convertible at the option of the holder into one common share of the company at a conversion price of $0.18 per share.
The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period.
All securities issued in connection with the private placement will be subject to a statutory hold period expiring on October 5, 2017.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: a third party potential licensees of TFC-1067 may not deliver a term sheet to the company in Q1 2017 or at all; the company may not be able to negotiate a license agreement with a potential licensees of TFC-1067 on terms acceptable to Sirona Biochem; the progress and timing of its clinical trials are uncertain; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing products; unexpected adverse side effects or inadequate therapeutic efficacy of the company’s or licensed products that could delay or prevent product development or commercialization; the scope and validity of patent protection for the company’s or licensed products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem, Technology
Sirona Biochem Announces Convertible Note Financing
Sirona Biochem Announces Convertible Note Financing
Momentum Public Relations
Press Release: May 31, 2017
VANCOUVER, BC–(Marketwired – May 31, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) announced today a non-brokered private placement (the “Private Placement”) of convertible notes (“Notes”) for gross proceeds of up to $500,000. Each Note will be convertible at the option of the holder into one common share of the company at a conversion price of $0.18 per share during the 18 month term of the Notes.
The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period. The Notes are unsecured and transferable, subject to resale restrictions under applicable securities laws and TSX Venture Exchange requirements.
All securities issued in connection with the private placement will be subject to a statutory hold period of four months commencing from the date of issuance of the Notes. Closing of the private placement is subject to customary conditions, including TSX Venture Exchange acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: a third party potential licensees of TFC-1067 may not deliver a term sheet to the company in Q1 2017 or at all; the company may not be able to negotiate a license agreement with a potential licensees of TFC-1067 on terms acceptable to Sirona Biochem; the progress and timing of its clinical trials are uncertain; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing products; unexpected adverse side effects or inadequate therapeutic efficacy of the company’s or licensed products that could delay or prevent product development or commercialization; the scope and validity of patent protection for the company’s or licensed products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem, Technology
Sirona Biochem (SBM:tsxv) Announces Keloid Data Accepted for Presentation to the Society of Investigative Dermatology
Sirona Biochem Announces Keloid Data Accepted for Presentation to the Society of Investigative Dermatology (SID)
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announced today that it has been accepted to present recent data at the 76th Annual Society of Investigative Dermatology (SID) Meeting, April 26-29 in Portland, Oregon. Sirona’s abstract, titled, Novel glycopeptide potential in keloid formation prevention and recurrence, will be presented as a poster during the 4-day conference.
The presentation outlines initial study results on the compound KEL-01. KEL-01 has been tested on normal human dermal fibroblasts (NF) and keloid fibroblasts (KF) for gene expression and protein expression.
In NF gene expression, KEL-01 downregulated genes involved in extracellular matrix (ECM) synthesis, collagen I, III and elastin, while it upregulated genes involved in ECM degradation, namely MMP1 and MMP3. In protein expression studies, the addition of KEL-01 significantly decreased the levels of collagen I and collagen III in KF. When KEL-01 was added to the KF, the ratio of collagen I/III was regulated to that of NF. An additional assay done showed activation of the Nrf2 pathway via KEL-01, which is down-regulated in keloids.
“We are pleased with the early results of KEL-01 on keloid fibroblasts,” said Dr. Howard Verrico, CEO. “Keloid scars are difficult to treat and there remains a significant unmet need for those prone to their development. We are planning studies on this compound in more advanced scar models.”
About the 76th Annual SID Meeting
The Society for Investigative Dermatology was founded in 1937 to highlight and promote discovery in investigative dermatology and to better represent skin-related scientific investigation amongst medical societies. Soon after, they launched the Journal of Investigative Dermatology (JID), a source for all advancements in cutaneous biology. The first Annual Meeting was held in New York City in 1938.
The 76th Annual Meeting, like those before it, will bring together researchers, lecturers, and industry leaders in dermatology. Throughout the four-day conference, cutting-edge research, findings and trends in skin health and disease will be shared. All abstracts will be published in upcoming editions of the JID.
Alongside lectures from leading experts in the field and poster presentations, there will be opportunities to talk to representatives from global companies about partnerships and collaborations.
For more information, please visit the conference website at http://www.sidnet.org/.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem